LENZ Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(14,619) | $(16,648) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 36 | 5 |
| Loss on impairment of operating right-of-use assets and related property and equipment | 82 | — |
| Accretion of discounts on marketable securities | (1,134) | (275) |
| Change in fair value of preferred stock warrants | — | 1,047 |
| Share-based compensation expense | 2,555 | 947 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (996) | (518) |
| Accounts payable | (771) | (1,269) |
| Accrued liabilities | (1,202) | (7,226) |
| Net cash used in operating activities | (16,049) | (23,937) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (33,091) | — |
| Proceeds from maturities of marketable securities | 52,090 | 18,000 |
| Purchases of property and equipment | (110) | — |
| Net cash provided by investing activities | 18,889 | 18,000 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | — | 53,387 |
| Cash, cash equivalents, and restricted cash acquired in connection with the Merger | — | 117,824 |
| Merger transaction costs | — | (373) |
| Proceeds from exercises of stock options | 44 | 430 |
| Net cash provided by financing activities | 44 | 171,268 |
| Net increase in cash, cash equivalents, and restricted cash | 2,884 | 165,331 |
| Cash and cash equivalents, and restricted cash, beginning of the period | 20,272 | 35,140 |
| Cash, cash equivalents, and restricted cash, end of the period | $23,156 | $200,471 |
| Supplemental cash flow information | ||
| Conversion of Series A, A-1, and B convertible preferred stock to common stock | $— | $137,490 |
| Conversion of Class B convertible common stock to common stock | $— | $5,900 |
| Reclassification of warrant liability to equity | $— | $1,918 |
| Prepaid expenses and other current assets assumed in the Merger | $— | $1,313 |
| Accounts payable and accrued liabilities assumed in the Merger | $— | $2,950 |
| Common stock issuance costs included in accounts payable and accrued expenses | $— | $3,547 |
| Merger transaction costs included in accounts payable and accrued expenses | $— | $4,815 |
| Right-of-use assets assumed in the Merger in exchange for operating lease liabilities | $— | $293 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.